Ticker

With well over 170 ETFs on the market covering diverse investment strategies, State Street offers a prime window into which funds — and market trends — are leading the pack in the near term. Key Takeaways: Across State Street's 170+ ETFs, the top five performers this past month are all tied to the healthcare industry.

The iShares U.S. Pharmaceuticals ETF is larger by assets under management and offers a higher trailing dividend yield. The State Street SPDR S&P Pharmaceuticals ETF has delivered higher one-year returns but experienced a much steeper maximum drawdown over five years.

Pharmaceuticals/biotechnology valuations and quality are near 11-year historical baselines, while healthcare equipment appears undervalued and life science tools least attractive. State Street SPDR S&P Pharmaceuticals ETF offers diversified pharmaceutical exposure with a modified equal-weight strategy, reducing company-specific risk versus capital-weighted peers. XPH is best suited for swing trading or tactical…

Invesco Nasdaq Biotechnology ETF offers a lower expense ratio and a higher trailing dividend yield than State Street SPDR S&P Pharmaceuticals ETF. State Street SPDR S&P Pharmaceuticals ETF has delivered a higher 1-year total return and experienced a less severe maximum drawdown than Invesco Nasdaq Biotechnology ETF.

State Street SPDR S&P Pharmaceuticals ETF provides exposure to 65 companies compared to the 25 holdings in VanEck Biotech ETF. VanEck Biotech ETF has experienced a deeper maximum drawdown of almost 40% over the last five years.